Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
The filing notifies sales of 10,946 shares of Common Stock via a stock option exercise reported as an issuer transaction on 04/01/2026. It also lists three reported open-market dispositions in the prior three months: 10,079 shares for $84,354.17, 10,349 shares for $80,339.29, and 10,312 shares for $78,471.23.
Fennec Pharmaceuticals is a commercial-stage specialty pharma company focused on preventing cisplatin-induced hearing loss with its drug PEDMARK in the U.S. and PEDMARQSI in Europe and other regions. The product is FDA- and European Commission-approved for pediatric patients with localized, non-metastatic solid tumors and showed about a 50% relative reduction in hearing loss versus cisplatin alone in clinical studies.
In March 2024, Fennec signed an exclusive licensing deal with Norgine, receiving about $43 million upfront, with up to about $230 million in potential milestones and double-digit tiered royalties on PEDMARQSI net sales. Norgine launched PEDMARQSI in Germany and the U.K. in 2025, with further European launches expected. Fennec also added a 2025 distribution agreement with Inpharmus for Turkey and Gulf Cooperation Council countries and reported positive 2025 Japanese STS-J01 trial results, supporting a registration strategy and potential partnering there.
The company has U.S. Orphan Drug Exclusivity for PEDMARK until September 20, 2029 and European pediatric-use marketing exclusivity until May 26, 2033, alongside a broad patent estate expiring around 2039. In March 2026, Fennec settled litigation with Cipla over a proposed generic, with Cipla agreeing not to launch its sodium thiosulfate product before September 1, 2033, reinforcing PEDMARK’s commercial runway.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share. This option exercise converts a derivative award into shares without any open-market buying or selling.
Following the transaction, Andrade directly holds 256,656 common shares. The filing reflects a compensation-related option exercise rather than a discretionary purchase or sale in the market.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi exercised stock options to acquire 4,700 common shares at an exercise price of $4.23 per share. Following the transaction, she holds 145,300 common shares directly, indicating an exercise-and-hold transaction with no reported share sales.
Fennec Pharmaceuticals reported strong growth in its core PEDMARK product but a wider loss for 2025. Net product sales reached $44.6 million for the year, up 50% from 2024, with Q4 2025 net product sales of $13.8 million, 75% above Q4 2024. Total 2025 revenue was $44.6 million versus $47.5 million in 2024, which had included one-time licensing revenue. Operating expenses rose to $51.4 million, leading to a full-year net loss of $10.1 million compared with a $0.4 million net loss in 2024. Cash and cash equivalents increased to $36.8 million as of December 31, 2025, and all term-loan debt was eliminated, helping turn shareholders’ equity from a deficit to a positive $35.1 million. The company highlighted record patient enrollments and an oversubscribed $42 million equity raise, along with positive clinical data supporting PEDMARK’s use in additional settings.
Fennec Pharmaceuticals Inc. reported that it has entered into a License Agreement with Cipla Limited and Cipla USA, Inc. to settle litigation over Cipla’s bid to market a generic version of Fennec’s PEDMARK® sodium thiosulfate injection. The lawsuit will be dismissed, with each party bearing its own costs. Cipla has agreed not to enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under specified circumstances. PEDMARK, Fennec’s FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in certain pediatric cancer patients, remains the only approved product of its kind and is protected by orphan drug exclusivity and patents the company states extend to 2039.
Fennec Pharmaceuticals filed an 8-K to highlight a new clinical research collaboration with the Tampa General Hospital Cancer Institute. The institute is initiating a real-world study of PEDMARK (sodium thiosulfate injection) to evaluate its clinical utility in reducing cisplatin-related hearing loss in adolescent, young adult and adult cancer patients.
PEDMARK is already FDA-approved to reduce ototoxicity in pediatric patients 1 month and older with localized, non-metastatic solid tumors and carries a 2A recommendation from the National Comprehensive Cancer Network for adolescent and young adult use. The study will analyze real-world clinical data and audiology monitoring to help guide future clinical research and quality efforts in managing ototoxicity.
Fennec Pharmaceuticals Inc. reported that its Chief Financial Officer, Robert Andrade, acquired 1,191 common shares as a grant or award at a price of $0.00 per share. A footnote explains these shares were released from restrictions on awards originally granted on 3/31/2023 and 5/16/2024. Following this transaction, Andrade directly owns 243,584 common shares.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported multiple equity transactions. On March 2, 2026, he exercised 15,598 stock options at $2.45 per share, receiving the same number of common shares under a 10b5-1 plan adopted on September 19, 2025. He then sold 10,079 common shares at $8.36 per share to cover tax obligations linked to the option exercise. On February 28, 2026, he also acquired 5,208 common shares at no cost as previously awarded shares were released from restrictions. After these transactions, his direct common share holdings were 103,996 shares.
Fennec Pharmaceuticals Inc. director Rostislav Raykov reported a proposed sale of 10,079 common shares, with an aggregate market value of $84,354.17 and an approximate sale date of March 2, 2026. The shares are listed as acquired from the issuer through a cash-paid stock option exercise on March 2, 2026; a Rule 10b5-1 plan adoption date of September 19, 2025 is also reported.